ARS Pharmaceuticals

Update in progress

SPRY (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions in the United States and internationally. It is developing Neffy, a needle-free, intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.

Company score

Sentiment: 0.13; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive